Marquette Asset Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-730
Closed -$17.1K 233
2024
Q2
$17.1K Hold
730
﹤0.01% 162
2024
Q1
$21K Sell
730
-120
-14% -$3.61K ﹤0.01% 157
2023
Q4
$27.9K Hold
850
0.01% 152
2023
Q3
$23.7K Hold
850
0.01% 161
2023
Q2
$29K Hold
850
0.01% 162
2023
Q1
$25.6K Buy
850
+730
+608% +$22.6K 0.01% 161
2022
Q4
$3.39K Buy
+120
New +$3.81K ﹤0.01% 198
2021
Q2
Sell
-120
Closed -$11K 236
2021
Q1
$11K Sell
120
-59
-33% -$5.85K ﹤0.01% 211
2020
Q4
$17K Buy
+179
New +$14.3K ﹤0.01% 205

Other funds holding ARKG

Marquette Asset Management's ARKG Position: Q3 2024 in Review

Marquette Asset Management sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2024, closing a stake of 730 shares — an estimated $17.1K sold.

Marquette Asset Management first reported a position in ARKG in Q4 2020 and held it in 9 quarters. The position peaked at $29K in Q2 2023. 238 funds tracked by Wall St. Rank hold ARKG as of Q3 2024.

  • Marquette Asset Management reported no remaining ARK Genomic Revolution ETF position as of Q3 2024 after selling out during the quarter.
  • Marquette Asset Management sold 730 ARK Genomic Revolution ETF shares in Q3 2024, an estimated $17.1K.
  • Marquette Asset Management first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 9 quarters.
  • Marquette Asset Management's ARK Genomic Revolution ETF position peaked at $29K in Q2 2023.
  • 238 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2024.

Based on Marquette Asset Management's 13F filing for Q3 2024, filed 8 Oct 2024.